Variability of response on prophylactic prasugrel for endovascular treatment of intracranial aneurysms: Clinical implications
Open Access
- 23 June 2023
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (6) , e0287190
Abstract
Prophylactic prasugrel for endovascular treatment of intracranial aneurysms has been introduced and increased, but HTPR (high on-treatment platelet reactivity) or LTPR (low on-treatment platelet reactivity) of prasugrel is not uncommon in clinical circumstances. To investigate the predisposing factors of HTPR and LTPR on prasugrel premedication in the neurointerventional field and to determine its clinical implications. Between February 2016 and December 2020, 191 patients treated with coil embolization using prophylactic prasugrel in 234 intracranial aneurysms were the final candidates for this study. Patient and aneurysm characteristics, clinical status, and laboratory study values were carefully reviewed retrospectively. We performed risk factor analyses for HTPR and LTPR on prasugrel. Ultimately, 20 patients (10.5%) had HTPR, and 74 patients (38.7%) were categorized as having LTPR. In multivariable analyses, the factors related to HTPR were BMI (adjusted OR 1.21, 95% CI 1.04–1.41, p = 0.01), history of antithrombotics (adjusted OR 3.79, 95% CI 1.39–10.34, p = 0.01), and hematocrit (adjusted OR 0.91, 95% CI 0.84–0.99, p = 0.03). Low BMI was the only risk factor for LTPR (adjusted OR 0.84, 95% CI 0.76–0.94, p = 0.001). In the neurointerventional field, high BMI and prior use of antithrombotic agents were related to HTPR, and low BMI was associated with LTPR on prophylactic prasugrel. High hematocrit levels decreased the risk of HTPR. When preparing endovascular treatment for intracranial aneurysms, attention to patients with these clinical features is required to address the possibility of ischemic or bleeding complications.Keywords
This publication has 32 references indexed in Scilit:
- CYP2C19*2 and *17 Alleles Have a Significant Impact on Platelet Response and Bleeding Risk in Patients Treated With Prasugrel After Acute Coronary SyndromeJACC: Cardiovascular Interventions, 2012
- Hemorrhagic complications after prasugrel (Effient) therapy for vascular neurointerventional proceduresJournal of NeuroInterventional Surgery, 2012
- Effect of Intrinsic and Extrinsic Factors on the Clinical Pharmacokinetics and Pharmacodynamics of PrasugrelClinical Pharmacokinetics, 2010
- Thromboembolic Complications of Elective Coil Embolization of Unruptured AneurysmsNeurosurgery, 2010
- Cytochrome P-450 Polymorphisms and Response to ClopidogrelNew England Journal of Medicine, 2009
- Prasugrel versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2007
- Effect of Antiplatelet Therapy on Thromboembolic Complications of Elective Coil Embolization of Cerebral AneurysmsAmerican Journal of Neuroradiology, 2007
- Outcomes Validity and Reliability of the Modified Rankin Scale: Implications for Stroke Clinical TrialsStroke, 2007
- Guglielmi Detachable Coil embolization of cerebral aneurysms: 11 years' experienceJournal of Neurosurgery, 2003
- Endovascular Treatment of Unruptured AneurysmsStroke, 2001